Table 2.

Change in height from baseline: median and 95% bootstrap CI estimates for each year of r-hGH therapy.

Endpoint	Severity	Year	fl/fl (median and 95% CI)	d3 carriers (median and 95% CI)	Difference (d3 carriers – fl/fl)
Change in height (cm)	Mild GHD	1	7.1 (6.6; 8.2)	8.3 (7.4; 8.6)	1.2
		2	14.1 (13.2; 15.0)	16.1 (14.3; 16.5)	2.0
		3	21.0 (19.7; 21.4)	23.7 (21.5; 24.0)	2.7
	Severe GHD	1	8.8 (8.0; 10.2)	7.8 (7.0; 9.3)	−1.0
		2	16.5 (14.5; 19.2)	13.9 (13.0; 15.9)	−2.6
		3	24.1 (21.7; 26.4)	20.8 (19.6; 23.6)	−3.3
Change in height SDS	Mild GHD	1	0.4 (0.3; 0.6)	0.5 (0.3; 0.7)	0.1
		2	0.6 (0.3; 0.8)	0.8 (0.5; 1.0)	0.2
		3	0.8 (0.5; 1.0)	1.0 (0.9; 1.2)	0.2
	Severe GHD	1	0.6 (0.6; 0.8)	0.5 (0.4; 0.7)	−0.1
		2	1.2 (0.8; 1.2)	0.7 (0.4; 0.9)	−0.5
		3	1.4 (1.1; 1.6)	1.1 (0.6; 1.3)	−0.3

GHD, growth hormone deficiency; r-hGH, recombinant human growth hormone.